- Home
- INTS vs BFRI Comparison
INTS vs BFRI Comparison
Compare INTS & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- BFRI
- Stock Information
- Founded
- INTS 2012
- BFRI 1997
- Country
- INTS United States
- BFRI United States
- Employees
- INTS N/A
- BFRI N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- INTS Health Care
- BFRI Health Care
- Exchange
- INTS Nasdaq
- BFRI Nasdaq
- Market Cap
- INTS 8.7M
- BFRI 7.5M
- IPO Year
- INTS 2023
- BFRI 2021
- Fundamental
- Price
- INTS $0.50
- BFRI $0.70
- Analyst Decision
- INTS Strong Buy
- BFRI Strong Buy
- Analyst Count
- INTS 3
- BFRI 1
- Target Price
- INTS $8.50
- BFRI $7.00
- AVG Volume (30 Days)
- INTS 396.2K
- BFRI 83.1K
- Earning Date
- INTS 05-13-2025
- BFRI 05-15-2025
- Dividend Yield
- INTS N/A
- BFRI N/A
- EPS Growth
- INTS N/A
- BFRI N/A
- EPS
- INTS N/A
- BFRI N/A
- Revenue
- INTS N/A
- BFRI $37,321,000.00
- Revenue This Year
- INTS N/A
- BFRI $18.57
- Revenue Next Year
- INTS N/A
- BFRI $20.17
- P/E Ratio
- INTS N/A
- BFRI N/A
- Revenue Growth
- INTS N/A
- BFRI 9.54
- 52 Week Low
- INTS $0.50
- BFRI $0.65
- 52 Week High
- INTS $5.28
- BFRI $2.22
- Technical
- Relative Strength Index (RSI)
- INTS 18.57
- BFRI 42.06
- Support Level
- INTS $0.46
- BFRI $0.66
- Resistance Level
- INTS $0.59
- BFRI $0.74
- Average True Range (ATR)
- INTS 0.05
- BFRI 0.06
- MACD
- INTS 0.02
- BFRI 0.00
- Stochastic Oscillator
- INTS 21.14
- BFRI 24.27
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.